Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Shares of Morgan Stanley (MS - Analyst Report) reached a new 52-week high, touching $27.00 in the last hour of the trading session on Jun 7, 2013. The closing price of this major global bank reflected a robust year-to-date return of 38.2%. The trading volume for the session was 32.75 million shares, significantly higher than the average 19.33 million shares over the last 3 months.

Despite the strong price appreciation, this Zacks Rank #3 (Hold) stock has plenty of upside left, given its estimate revisions over the last 60 days and expected year-over-year earnings growth of 33.9% for 2013.

Growth Drivers

Impressive first-quarter 2013 results, the underlying strength in its business segments as well as a strong capital position were the primary growth drivers for Morgan Stanley.

In early May 2013, at the time of filing its latest quarterly documents with the SEC, Morgan Stanley lowered its first-quarter adjusted earnings from continuous operations by a penny to 60 cents per share. Nevertheless, this was above the Zacks Consensus Estimate of 57 cents.

Additional legal expenses led Morgan Stanley to restate its earnings. However, favorable results were driven by lower operating expenses, partially offset by a fall in the top line. Moreover, increase in net revenue across all segments was the tailwind.

Estimate Revisions Show Potency

Over the last 60 days, 3 out of 15 estimates for 2013 have been revised upward, lifting the Zacks Consensus Estimate by 1.0% to $2.13 per share. For 2014, 2 out of 15 estimates moved higher over the same time frame, helping the Zacks Consensus Estimate advance 1.2% to $2.59 per share.

Better performing banks include Fifth Third Bancorp (FITB - Analyst Report), JPMorgan Chase & Co. (JPM - Analyst Report)  and State Street Corporation (STT - Analyst Report) all of which carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ANI PHARMACE ANIP 29.00 +13.50%
ATLAS FINANC AFH 14.57 +2.32%
FEDERATED NA FNHC 20.30 +2.16%
BIO PATH HOL BPTH 2.75 +1.48%
GREEN PLAINS GPRE 29.33 +1.31%